The circular RNA 001971/miR-29c-3p axis modulates colorectal cancer growth, metastasis, and angiogenesis through VEGFA

Chen Chen 1, Zhiguo Huang 2, Xiaoye Mo 2, Yanmin Song 2, Xiangmin Li 2, Xiaogang Li 2 and Mu Zhang 2*

Abstract

Background: Colorectal cancer (CRC) is one of the most common malignant tumors globally. Angiogenesis is a key event maintaining tumor cell survival and aggressiveness. The expression of vascular endothelial growth factor A (VEGFA), one of the most significant tumor cell-secreted proangiogenic factors, is frequently upregulated in CRC.

Methods: The MTT assay was used to detect the viability of CRC cells. Transwell assays were performed to detect the invasion capacity of target cells. Relative protein levels were determined by immunoblotting. Pathological characteristics of tissues were detected by H&E staining and immunohistochemical (IHC) staining. A RIP assay was conducted to validate the predicted binding between genes.

Results: We observed that circ-001971 expression was dramatically increased in CRC tissue samples and cells. Circ-001971 knockdown suppressed the capacity of CRC cells to proliferate and invade and HUVEC tube formation in vitro, as well as tumor growth in mice bearing SW620 cell-derived tumors in vivo. The expression of circ-001971 and VEGFA was dramatically increased whereas the expression of miR-29c-3p was reduced in tumor tissue samples. Circ-001971 relieved miR-29c-3p-induced inhibition of VEGFA by acting as a ceRNA, thereby aggravating the proliferation, invasion and angiogenesis of CRC. Consistent with the above findings, the expression of VEGFA was increased, whereas the expression of miR-29c-3p was decreased in tumor tissue samples. miR-29c-3p had a negative correlation with both circ-001971 and VEGFA, while circ-001971 was positively correlated with VEGFA.

Conclusions: In conclusion, the circ-001971/miR-29c-3p axis modulated CRC cell proliferation, invasion, and angiogenesis by targeting VEGFA.

Keywords: Colorectal cancer (CRC), Metastasis, Angiogenesis, Circ-001971, miR-29c-3p
cells to metastasize from the primary tumor site to distant organs.

Angiogenesis is a process of vascular remodeling, that is characterized by neovascularization from an existing blood vessel. Angiogenesis widely occurs in the process of fetal development, menstrual cycle and wound closure. In addition, angiogenesis can be found in numerous stages of fetal development, menstrual cycle and wound closure. Angiogenesis is characterized by neovascularization from an existing blood vessel. Angiogenesis widely occurs in the process of tumor growth and metastasis of tumors. As far back as 1963, it was reported that the size of tumors transplanted into isolated perfused organs did not exceed several millimeters [7]. Nevertheless, the tumors transplanted into mice could quickly grow to more than 1 cm³ and eventually kill their hosts [8]. Within isolated perfused organs the tumors did not become vascularized, but they did in mice [9]. Thus, in advanced stages of tumor growth, a more efficient vascular system is needed to provide nutrients and to clear metabolites. In fact, within tumor-related practices, inhibition of angiogenesis, primarily by blocking the VEGF (vascular endothelial growth factor) family and the corresponding receptors, has been strongly confirmed to confer clinical benefits, and to prolong the overall survival of treated patients with specific types of diseases, including CRC [6].

The VEGF family and the corresponding receptors play a critical role in microangiogenesis, and can be considered to have prognostic significance for virtually every type of tumor. The VEGF family and the corresponding receptors, the most important angiogenic regulators, frequently show overexpression in metastatic CRC and are directly related to the tumor vascularization degree, tumor growth and the poor prognosis of patients [10]. Among all VEGF family members, VEGFA (vascular endothelial growth factor A) is regarded as one of the most significant tumor cell-secreted proangiogenic factors [11, 12]. The potent impact of blood VEGF levels as a predictive biomarker was evaluated in studies involving the efficacy of the antiangiogenic drug cediranib in metastatic CRC, and the neovascularization involved in VEGFA signaling is considered to be a critical mediator of the factor for the angiogenesis, invasion and spread of tumors [13]. High baseline VEGFA levels correlate with poor progression-free and overall survival [14] and enhanced malignant tumor spread [15, 16]. Bevacizumab is a potent humanized monoclonal antibody to VEGF that, when combined with standard chemotherapy, results in an overall survival of approximately 24 months compared to approximately 20 months for standard chemotherapy alone [13, 17]. Recent reports have revealed that several miRNAs targeting by VEGFA, such as miR-203 [18], miR-497 [19], miR-26a [20], and miR-199a-5p [21], have antitumor effects. Thus, further investigation of the mechanism of abnormal upregulation of VEGFA in CRC might provide novel strategies for metastatic CRC treatment.

According to the latest high-throughput studies on the human transcriptome, approximately 85% of the human genome can be transcribed dynamically and generally mostly as non-coding RNAs (ncRNAs) [22–24]. During the past ten years, many observations have reasonably proposed that ncRNAs remarkably participate in complex molecular signaling, which is necessary for structural and functional regulation in various cells and development environments [25]. Therefore, active dysregulation of ncRNAs has been regarded as a crucial factor in the initiation and progression of different pathological conditions [26–27]. The basal expression of circular RNAs (circRNAs), a new class in the ncRNA network, has been detected in human cells and has a strong impact on the posttranscriptional regulation of gene expression [28–29]. Unlike the other two types of ncRNAs, noncoding RNAs (IncRNAs) and microRNAs (miRNAs), circRNAs have covalently linked ends [30]. Gene expression is regulated by some a number of circRNAs that act as ceRNAs (competing endogenous RNA) [31], also recognized as sponges for miRNAs, to affect the activity of miRNAs [32, 33]. CircRNAs prevent miRNAs from regulating of their target genes [34, 35]. Through further studies on circRNAs, we can provide an in-depth understanding of pathological mechanisms and more effective prevention and diagnosis of the related diseases.

In the present study, previously reported upregulated circRNAs were selected and analyzed to identify circRNAs that may modulate CRC invasion and angiogenesis. Then, the effects of circ-001971 on the capacity of CRC cells to proliferate and to invade on HUVEC tube formation and tumor growth in mice bearing SW620 cell-derived tumors were examined. Next, miRNAs that may target circ-001971 and VEGFA were selected and verified. The dynamic effect of circ-001971/miR-29c-3p on CRC invasion and angiogenesis was examined. Finally, circ-001971, miR-29c-3p, and VEGFA expression and correlation in tissue specimens were determined. Overall, we aimed to provide a new mechanism by which the circ-001971/miR-29c-3p/VEGFA axis modulates CRC invasion and angiogenesis.

Materials and methods

Clinical specimens, cell lines and cell culture

The present study was approved by Xiangya Hospital, Central South University. Colorectal cancer (T) and matched non-cancerous tissues (N) were obtained from 70 CRC patients who underwent primary surgical resection at Xiangya Hospital with written consent and stored...
at – 80 °C until further use. All clinicopathologic features of the patients are listed in Tables 1 and 2.

The normal colon epithelial cell line FHC was purchased from ATCC (Manassas, VA, USA). Five CRC cell lines, HT29, HCT116, LoVo, SW480 and SW620, were characterized in detail and were provided by ATCC. Cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in a humidified incubator under 5% CO2 at 37 °C.

H&E staining and immunohistochemical (IHC) staining
The tissue samples were excised, washed with PBS, arrested in diastole with 10% potassium chloride solution, weighed, placed in 10% formalin, and embedded in paraffin. Several sections (4–5 mm thick) were prepared, stained with hematoxylin and eosin (H&E) for histopathology by standard procedures and then visualized by light microscopy. For IHC staining, the content of VEGFA was detected by IHC following the previously described method [36]. After deparaffinization, hydration and blockage of endogenous peroxidase, the sections were incubated for 20 min with 10% nonfat milk in PBS in order to block specific sites and then were incubated at 4°C overnight with primary anti-VEGFA antibody (ab1316, abcam, USA). Then, sections were washed and incubated with HRP-conjugated goat anti-mouse secondary antibody (SV-0004, Boster, China) for 30 min at 37°C. Finally, the sections were washed and incubated with a DAB kit (AR1022, Boster) for 1 min.

Cell viability determined by the MTT assay
The MTT assay was used to detect the viability of CRC cells. Cells were cultured in 96-well plates (5 × 10⁴ cells/well). Twenty-four hours after plating the cells were attached, and 10 μL MTT was added to the fresh medium to replace the old medium. Four hours after incubation with the medium containing MTT at 37°C, the medium was discarded, and DMSO (100 μL) was added to each well after discarding the medium. After that, the absorbance was measured at 490 nm. The results are presented as percentage inhibition compared to the untreated control.

DNA synthesis assays
The ability to synthesize DNA was detected by 5-ethyl-2′-deoxyuridine (EdU) assays using an EdU assay kit (Guangzhou RiboBio Co., Ltd.) according to the manufacturer’s instructions. Briefly, cells were incubated with EdU for 24 and 48 h in the dark. Then, the cells were fixed with 4% paraformaldehyde for 30 min and stained with Apollo 567 solution for 30 min at room temperature in the dark. The inflorescence absorbance value of each well was determined by a multifunction microplate reader (Bio-Rad, USA).

Tube formation
The human umbilical vein endothelial cell line HUVEC was purchased from ATCC and seeded in 24-well plates coated with Matrigel (90 μL), incubated at 37°C for 30 min to polymerize, and then seeded in wells under different SW620 cell-conditioned media (CM) as described. The 24-well plates were incubated for 6 h, and tube formation was then imaged under an inverted microscope at a × 200 magnification.

Transwell invasion assay
Transwell assays were performed to detect the invasion capacity of target cells. Cells (5 × 10⁵) were plated on the upper chamber of a polycarbonate Transwell filter (Cell Biolabs, Inc. Santiago, USA) coated with Matrigel using serum-free medium. In the bottom chamber, serum-containing medium was used as a chemoattractant. After

| Clinic-pathological parameters | circ-001971 expression | p         |
|-------------------------------|------------------------|-----------|
|                               | High       | Low       |
| Gender                        |            |           |
| female                        | 20         | 21        | 0.808    |
| male                          | 15         | 14        |          |
| Age                           |            |           |
| < 50                          | 21         | 15        | 0.151    |
| ≥ 50                          | 14         | 6         |          |
| Tumorlocation                 |            |           |
| Left                          | 10         | 14        | 0.435    |
| Rectum                        | 15         |           |          |
| Right                         | 16         | 6         |          |
| TNM                           |            |           |
| I                             | 2          | 11        | <0.001   |
| II                            | 5          | 17        |          |
| III                           | 13         | 5         |          |
| IV                            | 5          | 2         |          |
| Differentiation               |            |           |
| Low                           | 21         | 15        | 0.151    |
| Moderate and High             | 14         | 20        |          |
| Tumor size                    |            |           |
| < 5                           | 17         | 22        | 0.229    |
| ≥ 5                           | 18         | 13        |          |
| Lymph node metastasis         |            |           |
| N0                            | 6          | 30        | <0.001   |
| N1                            | 18         | 2         |          |
| N2                            | 11         | 3         |          |
incubating at 37 °C for 48 h, the noninvasive cells in the top chambers were removed and the invaded cells on the lower membrane surface were fixed with 100% methanol, stained with DAPI (Beyotime Institute of Biotechnology, Haimen, China), and counted under a microscope.

Expression levels determined by polymerase chain reaction (PCR)-based analysis

For miRNA, circRNA and mRNA expression determination, we extracted total RNA using TRIzol reagent (Invitrogen) following the manufacturer’s instructions. For miRNA expression determination, reverse transcription was conducted using miRNA-specific primers and a miScript Reverse Transcription kit (Qiagen, Germany) taking RNU6B expression as an endogenous control. For mRNA expression determination, SYBR green PCR Master Mix (Qiagen) was used, using GAPDH expression as an endogenous control. For circRNA expression determination, the total RNA was digested by Ribonuclease R (Epicentre, USA), and then the RNA was reverse transcribed and subjected to RT-PCR using SYBR green PCR Master Mix (Qiagen). RT-PCR assays with divergent or convergent primers were used for circRNA identification (Fig. S1). The relative fold-change was calculated by the $2^{-\Delta\Delta CT}$ method. The primer sequences are listed in Table S1.

Table 2  Univariate and multivariate analysis for factors related to overall survival using the COX proportional hazard model

| Variable               | Univariate analysis | Multivariate analysis |
|------------------------|---------------------|-----------------------|
|                        | p-value | HR  | 95%CI | p-value | HR  | 95%CI |
| Gender                 |          |     |       |          |     |       |
| Female                 | 0.632    | 0.840 | 0.411–1.716 |          |     |       |
| Male                   |          |     |       |          |     |       |
| Age                    |          |     |       |          |     |       |
| < 50                   | 0.926    | 1.034 | 0.511–2.092 |          |     |       |
| ≥ 50                   |          |     |       |          |     |       |
| Tumorlocation          |          |     |       |          |     |       |
| Left                   | 0.661    |     |       |          |     |       |
| Rectum                 | 0.642    | 1.247 | 0.491–3.170 |          |     |       |
| Right                  | 0.753    | 0.861 | 0.339–2.188 |          |     |       |
| TNM                    |          |     |       |          |     |       |
| I                      | 0.000    |     |       | 0.000    |     |       |
| II                     | 0.000    | 0.011 | 0.002–0.082 | 0.000    |     | 0.008 | 0.001–0.097 |
| III                    | 0.000    | 0.022 | 0.004–0.111 | 0.000    |     | 0.012 | 0.001–0.138 |
| IV                     | 0.000    | 0.070 | 0.016–0.306 | 0.000    |     | 0.047 | 0.011–0.212 |
| Differentiation        |          |     |       |          |     |       |
| Low                    | 0.231    | 1.547 | 0.537–4.92 |          |     |       |
| Moderat and High       |          |     |       |          |     |       |
| Tumor size             |          |     |       |          |     |       |
| < 5                    | 0.606    | 0.831 | 0.411–1.681 |          |     |       |
| ≥ 5                    |          |     |       |          |     |       |
| Lymph node metastasis  |          |     |       |          |     |       |
| N0                     | 0.001    |     |       |          |     |       |
| N1                     | 0.005    | 0.253 | 0.098–0.663 | 0.227    | 3.552 | 0.454–27.791 |
| N2                     | 0.718    | 2.974 | 0.492–28.01 | 0.667    | 1.217 | 0.497–2.978 |
| circ-001971            |          |     |       |          |     |       |
| High                   |          |     |       |          |     |       |
| Low                    | 0.000    | 6.785 | 2.764–16.654 | 0.001    | 6.456 | 2.060–20.232 |
**Tumorigenicity assay in mice**

Six BALB/c nude male mice (4 weeks old) were used in the experiments. All animals were randomly assigned into two groups. SW620 cells, infected with Lv-sh-NC or Lv-sh-circ-001971 (GeneChem, China) were suspended in 200 μl growth medium/Matrigel and subcutaneously injected into the left axillaries of mice in the different groups. Twenty-five days after the injection, mice were sacrificed under anesthesia. The length (L) and width (W) of the tumors were measured and the tumor volumes (V) were calculated following the formula $V = L \times W^2/2$ every 5 days for 25 days. At the end of the animal experiments, the tumor weights in the two groups were determined.

**Protein levels determined by immunoblotting**

RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) was used to lyse the target cells and a complete protease inhibitor cocktail (Roche, USA) was used for total protein collection. Then, total proteins were separated using SDS-PAGE and transferred onto PVDF membranes. The antibodies listed below were used to incubate the blots at 4 °C overnight: anti-VEGFA (ab1316) and anti-GAPDH (ab8245, Abcam). The membranes were then incubated with an HRP-conjugated secondary antibody (1:5000). Signals were visualized using ECL (enhanced chemiluminescence) substrates (Millipore, USA) using endogenous GAPDH levels for normalization.

**Luciferase reporter assay**

For miR-29c-3p binding to circ-001971 or the 3'UTR of VEGFA, the fragment of circ-001971 or the 3'UTR of VEGFA was amplified by PCR and cloned downstream of the Renilla gene in the psiCHECK-2 vector (Promega, Madison, WI, USA), which was named wt-circ-001971 or wt-VEGFA 3'UTR. To generate the circ-001971, VEGFA 3'UTR mut-3'UTR reporters, the seed region of the circ-001971 and the VEGFA 3'UTR were mutated to remove the complementarity to miR-29c-3p, and the resulting constructs were named mut-circ-001971 and mut-VEGFA 3'UTR. HEK293 cells (ATCC, USA) were seeded into a 24-well plate. Then, HEK293 cells were cultured overnight and cotransfected with a luciferase reporter vector and miR-29c-3p mimics/inhibitor. After 48 h, the alterations in the luciferase activity were evaluated by the Dual-Luciferase Reporter Assay System (Promega) using firefly luciferase activity for normalization.

**RNA immunoprecipitation (RIP)**

RIP assay was conducted to validate the predicted binding. A Magna RIP RNA-Binding Protein Immunoprecipitation Kit (17–700; Millipore, Burlington, MA, USA) according to the product’s instructions. The immuno-precipitated RNAs were reverse transcribed and subjected to RT-PCR using the PrimeScript™ RT reagent Kit (Takara, Japan) and SYBR Green PCR Master Mix (Qiagen). miR-29c-3p, circ-001971, and VEGFA levels in the immunoprecipitates were detected using specific primers.

**Statistical analysis**

Each experiment was repeated at least three times. Data were processed by SPSS 17.0 and presented as the mean ± S.D. Differences between two groups were compared using Student’s t-test; differences among more than two groups were compared using one-way ANOVA followed by Turkey’s test. Pearson Correlation analysis was used to determine the relationships among miR-29c, circ-001971 and VEGFA. Kaplan-Meier analysis of overall survival by the log-rank test was used for overall survival analysis. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic and prognostic sensitivity and specificity of circ-001971 for CRC. *P < 0.05; **P < 0.01.

**Results**

**Selection of circ-001971**

These samples were collected and verified by H&E staining (Fig. 1a). To identify circRNAs that might be related to CRC carcinogenesis, the top 11 upregulated circRNAs previously reported to be highly expressed in CRC tumor tissue samples compared with normal mucosa tissue samples (Table S2) [37], were selected for real-time PCR confirmation. Figure 1b shows that in 13 paired tumor and noncancerous tissue specimens, circ-002739, circ-001971 and circ-004028 were significantly upregulated in tumor specimens than in normal mucosa tissue. Thus, circ-001971 was selected for further experiments.

In 70 paired tissue specimens, circ-001971 expression was significantly upregulated, consistent with the previous small sample size examination (Fig. 1c). Next, we analyzed circ-001971 expression according to the TNM stage and found that circ-001971 expression was higher in specimens at advanced TNM stages (III + IV) than in specimens at early stages (I + II; Fig. 1d). To further validate the effect of circ-001971 on CRC, the association between the expression of circ-001971 and the clinical indicators of CRC patients was detected. Seventy cases were assigned into two groups, high and low circ-001971 expression groups, by the median value of circ-001971 expression. Table 1 shows that high circ-001971 expression was dramatically related to advanced TNM stages and lymphatic metastasis. Moreover, we employed a Cox proportional hazards regression model to detect the overall survival rate and pathologic features of the 70 CRC patients. Univariate analysis revealed that the TNM stage, lymph node metastasis and circ-001971 expression
caused remarkable differences in the overall survival rate. Mutivariable analysis demonstrated that the TNM stage and circ 001971 expression led to the differences in overall survival rate with statistical significance (Table 2). To determine circ-001971 as a biomarker of CRC, we performed ROC curve analysis to evaluate the diagnostic (Fig. 1e) and prognostic (Fig. 1g) sensitivity and specificity of circ-001971 for CRC. The area under the curve was 0.788 (Fig. 1e) or 0.792 (Fig. 1g), which shows that circ-001971 has a potential diagnostic and prognostic capability (Fig. 1e and g). Kaplan-Meier curves of overall survival by log-rank test demonstrated
that the overall survival rate of patients in the low circ-001971 expression group was higher (Fig. 1f), suggesting the underlying effect of circ-001971 on CRC.

The effects of circ-001971 on the proliferation and invasion of CRC cells and the angiogenesis of HUVECs
To investigate the specific functions of circ-001971 in CRC carcinogenesis, we examined its expression in five CRC cell lines (HT29, HCT116, LoVo, SW480, and SW620) and a normal cell line, FHC. Consistent with its expression in tissues, the expression of circ-001971 was significantly increased within CRC cells compared with FHC cell lines (Fig. 2a) and was more highly increased in HCT116 and SW620 cells (Fig. 2a). We transfected si-circ-001971#1 and si-circ-001971#2 to conduct circ-001971 knockdown in HCT116 and SW620 cells, and performed real-time PCR to verify the transfection efficiency. Then, we selected si-circ-001971#1 as the siRNA targeting circ-001971 because of its greater efficiency (Fig. 2b).

Next, we transfected HCT116 and SW620 cell lines with si-circ-001971 and determined the proliferation and invasion of cells. After knocking down circ-001971, the DNA synthesis capacity (Fig. 2c), cell viability (Fig. 2d-e), and cell invasion (Fig. 2f-g) were all significantly inhibited. To further investigate the effects of circ-001971 on HUVEC tube formation through the tumor microenvironment, we collected conditioned medium from circ-001971-knockdown or control SW620 cells (si-circ-001971 CM and si-NC CM), cultured HUVECs in these two CM, respectively, and examined HUVEC angiogenesis in different CM. Figure 2h-i shows that culture with si-circ-001971 CM significantly suppressed HUVEC tube formation compared with culture in si-NC CM.

Effects of circ-001971 on CRC growth in vivo
To further confirm the tumor suppressor roles of circ-001971 knockdown, we constructed lentivirus containing shRNA targeting circ-001971 (Lv-sh-circ-001971) and performed real-time PCR to verify the knockdown efficiency (Fig. 3a). Next, six animals were randomly assigned into two groups (n = 3), and SW620 cells infected with Lv-sh-NC (negative control) or Lv-sh-circ-001971, were hypodermically injected into the left axillaries of the mice in these two groups (Fig. 3b). As shown in Fig. 3c and d, circ-001971 knockdown significantly reduced the tumor volumes at every measurement time point and reduced the tumor weight determined at the end of the experiment. These data indicate that circ-001971 knockdown inhibits CRC tumor growth in vivo.

Selection and verification of miRNAs related to circ-001971 and CRC angiogenesis
CircRNAs act as miRNA sponges to offset miRNA-induced inhibition of downstream target genes [38]. To investigate the molecular mechanism of circ-001971 functioning in CRC growth and metastasis, we screened for miRNAs that may be related to CRC metastasis and may target VEGFA, a key regulator of tumor angiogenesis [39]. According to the online microarray expression profile GSE126093, a total of 440 miRNAs were upregulated and 74 were down-regulated in CRC tissue samples than that within normal control tissue samples (p < 0.05, \(|\log FC| > 0.6\) (Fig. 4a). In circ-001971 knocked-down HCT116 and SW620 cells, the protein levels of VEGFA were also significantly decreased (Fig. 4b-c), suggesting the potential crosstalk between circ-001971 and VEGFA. Next, we employed TargetScan to predict miRNAs that might target VEGFA. Among the 627 predicted miRNAs, 16 miRNAs were down-regulated in CRC reported by GSE126093. Among the 16 miRNAs, 3 were predicted to target circ-001971, namely, miR-29c-3p, miR-497-5p, and miR-943 (Fig. 4d).

To further confirm the miRNA that might mediate the crosstalk between circ-001971 and VEGFA, we transfected miRNA mimics to overexpress the three candidate miRNAs in HCT116 and SW620 cells, and performed real-time PCR to verify the transfection efficiency (Fig. 4e). Next, we transfected HCT116 and SW620 cell lines with miRNA mimics and examined the expression of circ-001971 and VEGFA. As shown in Fig. 4f and g, all three miRNAs inhibited the expression of VEGFA within both CRC cells, however, only miR-29-3p strongly inhibited circ-001971 expression within both CRC cell lines. Thus, we selected miR-29c-3p for further experiments.

We transfected miR-29c-3p inhibitor to conduct miR-29c-3p inhibition within HCT116 and SW620 cell lines, as confirmed by real-time PCR (Fig. 4h). In miR-29c-3p inhibited HCT116 and SW620 cells, circ-001971 expression was significantly upregulated (Fig. 4i); in circ-001971 knockdown HCT116 and SW620 cell lines, miR-29c-3p expression was dramatically upregulated (Fig. 4i). Moreover, within HCT116 and SW620 cell lines, miR-29c-3p overexpression dramatically decreased, while miR-29c-3p inhibition increased VEGFA protein levels (Fig. 4k-l).

miR-29c-3p directly binds to circ-001971 and VEGFA
To investigate the putative miR-29c-3p binding to circ-001971 and VEGFA, we performed luciferase reporter and RIP assays. We constructed two kinds of reporter vectors, wild-type and mutant, which named wt-circ-001971/mut-circ-001971 and wt-VEGFA 3’UTR/mut-VEGFA 3’UTR, respectively. In the mutant reporter
vectors, 4 bases were mutated in the predicted miR-29c-3p binding site of (Fig. 5a and c). Next, we cotransfected HEK293 cells with these vectors and miR-29c-3p mimics/inhibitor, and determined the luciferase activity. Wild-type vector (wt-circ-001971 and wt-VEGFA 3'UTR) luciferase activity was dramatically reduced via the overexpression of miR-29c-3p, and it was increased via the inhibition of miR-29c-3p. Once the putative binding site was mutated, the luciferase activity was reduced to almost the original value (Fig. 5b and d). To further confirm the binding, RIP assays were performed. Based on the results, circ-001971, VEGFA and miR-29c-3p were associated with AGO2; in RNA extracted from the protein precipitate, circ-001971, VEGFA and miR-29c-3p levels were twice as high as those in the IgG sample (Fig. 5e). Moreover, endogenous circ-001971 and VEGFA pull-down by AGO2 was enriched after miR-29c-3p overexpression (Fig. 5f). These data confirmed that circ-001971 and VEGFA bind to miR-29c-3p in an AGO2-associated manner.

Fig. 2 The effect of circ-001971 on CRC cell invasion and HUVEC tube formation (a) The expression of circ-001971 in five CRC cell lines, HT29, HCT116, LoVo, SW480, and SW620, and a normal cell line was examined using real-time PCR. b The knockdown of circ-001971 was achieved in HCT116 and SW620 cells by transfection with si-circ-001971#1 or si-circ-001971#2, as confirmed using real-time PCR. (C-E) HCT116 and SW620 cells were transfected with si-circ-001971 and examined for DNA synthesis (c) and cell proliferation (d-e). f-g HCT116 and SW620 cells were transfected with si-circ-001971 and examined for cell invasion using Transwell assays. h-i We collected conditioned medium from circ-001971 knockdown or control SW620 cells (si-circ-001971 CM and si-NC CM), cultured HUVECs in these two CM samples, and examined for the tube formation capacity. The data are presented as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, compared to FHC cells or the si-NC group.
The circ-001971/miR-29c-3p axis modulates the tube formation capacity of HUVECs

After confirming circ-001971 binding to miR-29c-3p, the study continued to investigate the dynamic effects of circ-001971 and miR-29c-3p on HUVEC tube formation. First, HCT116 and SW620 cells were cotransfected with miR-29c-3p inhibitor and si-circ-001971, and the protein levels of VEGFA were examined. As shown in Fig. 6a-b, in both cell lines, miR-29c-3p inhibition increased, while circ-001971 knockdown decreased the protein levels of VEGFA, and the effects of circ-001971 knockdown on VEGFA protein levels were significantly reversed by miR-29c-3p inhibition. Then, different CM samples were collected for HUVEC culture. As shown in Fig. 6c-d, miR-29c-3p inhibition significantly enhanced, while circ-001971 knockdown inhibited the tube formation ability of HUVECs and the effects of circ-001971 knockdown on HUVEC tube formation were significantly reversed by miR-29c-3p inhibition. Overall, these data indicate that the circ-001971/miR-29c-3p axis could modulate VEGFA protein levels and HUVEC tube formation.

miR-29c-3p and VEGFA expression in tissue samples and their correlation with circ-001971

As a further confirmation, we performed real-time PCR to examine miR-29c-3p and VEGFA expression in tissue samples. Figure 7a-b shows that the expression of miR-29c-3p was obviously inhibited while the expression of VEGFA was enhanced within tumor tissues compared with non-cancerous tissue samples. Consistent results were revealed obtained by IHC and immunoblotting assays that VEGFA protein contents within tumor tissue samples showed to be increased as compared to those within non-cancerous tissue samples (Fig. 7c-d). In addition, miR-29c-3p was negatively related to circ-001971 and VEGFA (Fig. 7e-f); circ-001971 was positively related to VEGFA (Fig. 7g).

Discussion

Herein, we demonstrate that the circ-001971/miR-29c-3p axis modulates CRC cell proliferation and invasion ability and HUVEC angiogenesis by targeting VEGFA. In rats bearing SW620 cell-derived tumors, circ-001971 knockdown significantly inhibited tumor growth compared to the control group. In tumor tissues, circ-001971 and VEGFA expression was significantly increased whereas miR-29c-3p expression was reduced, further suggesting that circ-001971 counteracts miR-29c-3p-induced inhibition of VEGFA by acting as a ceRNA, therefore aggravating CRC growth, metastasis, and angiogenesis.

The dysregulation of ncRNAs in CRC has been widely reported. Xiong et al. reported that 2662 lncRNAs and 2398 mRNAs in total were differentially expressed in 5-FU-based chemoradiation resistant HCT116 cells. By using KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis, they observed that the related signaling pathways, including the JAK-STAT, PI3K-Akt and NF-kappa B signaling pathways, were involved in CRC progression [40]. Moreover, miRNA-mRNA crosstalk and its effects on CRC have been widely studied [41], whereby each CRC metastatic process, consisting of new blood vessel formation, invasion, intravascular perfusion, circulation, extravasation, and metastatic colonization could be impacted by these miRNAs [42]. Unlike these two kinds of ncRNAs, the role and
Fig. 4 (See legend on next page.)
(See figure on previous page.)

**Fig. 4** Selection and verification of miRNAs related to circ-001971 and CRC angiogenesis (a) Upregulated and downregulated miRNAs in CRC tissues compared to that in noncancerous tissues according to the online microarray expression profile GSE126093. (b-e) HCT116 and SW620 cells were transfected with si-circ-001971, and the protein levels of VEGFA were examined by immunoblotting. (d) TargetScan was used to predict miRNAs that might target VEGFA. Among the 627 predicted miRNAs, 16 miRNAs were downregulated miRNAs in CRC, as reported by GSE126093. Among the 16 miRNAs, 3 were predicted to target circ-001971, including miR-29c-3p, miR-497-5p, and miR-943. (e) Overexpression of the three candidate miRNAs was conducted in HCT116 and SW620 cells by the transfection with miRNA mimics. The transfection efficiency was confirmed by real-time PCR. Then, HCT116 and SW620 cells were transfected by miRNA mimics and examined for (f) the expression of circ-001971 by real-time PCR and (g) the expression of VEGFA by real-time PCR. miR-29c-3p was selected for further experiments. (h) miR-29c-3p inhibition was conducted in HCT116 and SW620 cells by the transfection of miR-29c-3p inhibitor. The transfection efficiency was verified by real-time PCR. (i) HCT116 and SW620 cells were transfected with miR-29c-3p inhibitor and the expression of circ-001971 was examined by real-time PCR. (k-l) HCT116 and SW620 cells were transfected by si-circ-001971 and examined for the expression of miR-29c-3p by real-time PCR. (K-L) HCT116 and SW620 cells were transfected with miR-29c-3p mimics or inhibitor, and the protein levels of VEGFA were by immunoblotting. **P < 0.05; ***P < 0.01, compared to si-NC, mimics-NC or inhibitor NC group.

**Fig. 5** miR-29c-3p directly binds to circ-001971 and VEGFA (a-b) Two different types of luciferase reporter vectors were constructed: wild-type circ-001971 and VEGFA 3’UTR, and mutant-type circ-001971 and VEGFA 3’UTR; mutant-type vectors contained a 4 bp mutation in the predicted miR-29c-3p binding site. (c-d) The above vectors were cotransfected into HEK293 cells with miR-29c-3p mimics or miR-29c-3p inhibitor and examined for luciferase activity. (e) RIP assays were performed to confirm the binding of miR-29c-3p to circ-001971 and VEGFA using an AGO2 antibody. The levels of miR-29c-3p, circ-001971 and VEGFA in precipitated AGO2 proteins were examined using real-time PCR. (f) Endogenous circ-001971 and VEGFA 3’UTR pull-down by AGO2 upon overexpression of miR-29c-3p was determined using RIP assays. The data are presented as the mean ± SD of three independent experiments. **P < 0.01, compared to mimics-NC, inhibitor-NC, IgG group.
mechanism of circRNAs in CRC need further investigation. According to Bachmayr et al. [43], we selected the 11 circRNAs that were most upregulated in CRC tissues for further investigation. Of them, circ-001971 expression was more upregulated in 13 CRC tissue specimens. Interestingly, circ-001971 expression was higher in specimens in advanced TNM stages, and high circ-001971 expression was significantly related to CRC patient adverse prognosis, indicative of the underlying effect of circ-001971 on CRC progression.

Tumor growth would be limited when tumors grow beyond 2–3 mm³ in size because of the lack of vasculature [44]. In this case, the angiogenic switch would be triggered for survival, and cancer cell invasion and metastasis would be promoted. Herein, circ-001971 knockdown significantly inhibited CRC cell proliferation and invasion and HUVEC angiogenesis, suggesting that circ-001971 may have a strong impact on CRC progression.

As further evidence, in rats bearing SW620 cell-derived tumors, knocking down circ-001971 significantly inhibited the growth of tumors, indicating that circ-001971 knockdown exerts a tumor-suppressive effect.

Regarding the molecular mechanism, circRNAs usually function by acting as miRNA sponges. One of the mechanisms by which hsa_circ-001569 enhanced the expression of the miR-145 functional targets E2F5, BAG4 and FMNL2 is by acting as a miR-145 sponge, while promoting the capacity of CRC cells to proliferate and invade [45]. Hsa_circ-0020397 inhibited the miR-138 activity on its downstream targets including TERT (telomerase reverse transcriptase) and PD-L1 (programmed death-ligand 1), and thus antagonized miR-138 suppression of CRC cell growth [46]. In the present study, miRNAs that may be related to CRC metastasis and may simultaneously target circ-001971 and VEGFA were selected. Of the three identified miRNAs, miR-29c-3p overexpression inhibited circ-001971 expression more than miR-497-5p and miR-943 did. Consistent with previously-reported circRNA-miRNA pairs, circ-001971 and miR-29c-3p negatively regulated each other. More importantly, miR-29c-3p negatively modulated the protein levels of VEGFA, suggesting that circ-001971 may exert its effect on CRC proliferation, invasion, and angiogenesis through miR-29c-3p.
As further evidence of online target prediction tools indicated that miR-29c-3p could directly target both circ-001971 and VEGFA. It has been revealed that miR-29c-3p serves as an antitumor miRNA in a number of cancers and its expression is downregulated in cancers including head and neck cancers [47], endometrial carcinoma [48], gastric cancer [49], and colorectal cancer [50]. Has-miR-29c-3p overexpression was shown to decrease the capacity of CRC cells to proliferate and migrate [50]. In the present study, consistent with the negative dual-regulation of circ-001971 and miR-29c-3p, HUVEC angiogenesis was remarkably attenuated via circ-001971 knockdown but enhanced via the inhibition of miR-29c-3p, while the inhibition of miR-29c-3p significantly attenuated the effect of circ-001971 knockdown. In addition, circ-001971/miR-29c-3p axis also modulated VEGFA protein levels. As we have mentioned, VEGFA expression is considered to be one of the most critical proangiogenic factors for tumor cell secretion [11, 12]. Herein, abnormally increased VEGFA protein levels in CRC cells were observed. Moreover, VEGFA protein levels could be dramatically decreased by circ-001971 silencing but enhanced via miR-29c-3p inhibition. In summary, miR-29c-3p and upstream circ-001971 exert their functions on CRC proliferation, invasion, and angiogenesis through VEGFA.

![Image of graphs and charts](Fig. 7)
Conclusions
As further evidence of the above findings, the expression of VEGFA was upregulated, whereas the expression of miR-29c-3p was downregulated in tumor tissue samples. miR-29c-3p was negatively correlated with circ-001971 and VEGFA, while circ-001971 was positively correlated with VEGFA. Overall, the circ-001971/miR-29c-3p axis modulates CRC proliferation, invasion, and angiogenesis through VEGFA. We provide a new rationale for the effect of the circRNA-miRNA-mRNA network on CRC progression.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13046-020-01594-y.

Additional file 1: Fig. S1. Identification of circ-001971. (A) RT-PCR assay with divergent or convergent primers indicating the existence of circ-001971 in SW620 cells. GAPDH was used as a negative control. cDNA: complementary DNA. gDNA: genomic DNA. (C) qRT-PCR analysis of the expression of circRNA-001971 after RNase R treatment in SW620 cells. "P < 0.01, compared to the RNAse R group.

Additional file 2: Table S1. The sequence of primers.

Additional file 3: Table S2. The top 11 upregulated circular RNA in CRC tumor tissue samples than normal mucosa tissue samples.

Abbreviations
CM: condition media; ceRNAs: Competing endogenous RNAs; circRNAs: Circular RNAs; CRC: Colorectal cancer; H&E: Hematoxylin and eosin; IHC: Immunohistochemical; KEGG: Kyoto Encyclopedia of Genes and Genomes; IncRNAs: Long non-coding RNAs; miRNAs: Non-coding RNAs; miRNAs: microm; PD-L1: Programmed death-ligand 1; ROCK: Rho operating characteristic; TERT: Telomerase reverse transcriptase; VEGFA: Vascular endothelial growth factor A

Acknowledgements
None.

Authors’ contributions
Chen Chen, Zhiguo Huang, Mu Zhang made substantial contribution to the conception and design of the study. Xiaoye Mo, Yanmin Song analyzed and interpreted the data. Chen Chen, Xiaomin Li drafted the manuscript. Xiaogang Li, Mu Zhang revised the work critically for important intellectual content. All authors read and approved the final manuscript.

Funding
This study was supported by the National Nature Science Foundation of China. (81802804).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
All procedures performed in studies involving human participants or animal were in accordance with the ethical standards of Xiangya Hospital and with the 1964 Helsinki declaration. Informed consent to participate in the study has been obtained from participants.

Consent for publication
Consent for publication was obtained from the participants.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China. 2Department of Emergency, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China.

Received: 17 February 2020 Accepted: 8 May 2020

Published online: 19 May 2020

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Scherer A, Gattl G. Targeted therapy of colorectal Cancer. Korean BioS Treat. 2016;39:796–802.
3. Tauriello DV, Battle E. Targeting the microenvironment in advanced colorectal Cancer. Trends Cancer. 2014;2:49–51.
4. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2003;25:247–53.
5. Camillet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.
6. Bagnasco L, Piras D, Parodi S, Bauso, Zeppoli G, Patrone F, Ballestro A. Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors. Curr Cancer Drug Targets. 2012;12:303–15.
7. Folkman J, Long AT, Peck R. Growth and metastasis of tumor in organ culture. Cancer. 1968;21:194–7.
8. Burdett S. Angiogenesis of the colon and antecedent epithelium. Cancer Res. 1997;57:5599–601.
9. Folkman J, Hsueh P. Angiogenic factors. Science. 1987;235:442–7.
10. Takahashi Y, Matada Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:56–8.
11. Unger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12:303–24.
12. P Leopardi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous non-small cell lung cancer. Drugs. 2014;74:403–13.
13. Grotthey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009;6:507–18.
14. Mousa L, Salem ME, Mikhal S. Biomarkers of angiogenesis in colorectal Cancer. Biomark Cancer. 2015;7:13–9.
15. Des Guetz G, Uzzan B, Nicolas P, Cuchet M, Moreire JF, Benamourt R, Breau JL, Perret GY. Microvesicle density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94:1823–32.
16. Ferroni P, Spila A, Martini F, D’Alessandro R, Marotti S, Del Monte G, Graziano P, Buonomo O, Guidagni F, Roselli M. Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. Oncology. 2005;69:145–53.
17. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg. 2006;93:1456–63.
18. Zhu X, Er K, Mao C, Yan Q, Xu H, Zhang Y, Zhu J, Cui F, Zhao W, Shi; miR-203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer. Cell Physiol Biochem. 2013;32:64–73.
19. Wang W, Ren F, Wu Q, Jiang D, Li H, Shi H. MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor through the PI3K/Akt and MAPK/ERK pathways in ovarian cancer. Oncol Rep. 2014;32:2127–33.
20. Cha ZT, Kong J, Zhu XD, Zhang YY, Lu L, Zhou JM, Wang LR, Zhang KZ, Zhang QB, Ao JY, et al. MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PI3K/Akt/Alf-1 pathway in hepatocellular carcinoma. PLoS One. 2013;8:e77957.
21. Hsu CY, Hsieh TH, Tsai CF, Tsai HP, Chen HS, Chang Y, Chuang HY, Lee JN, Hsu YL. Tsai EM: miRNA-199a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis. J Pathol. 2014;222:330–43.
22. Prashant KV, Spector DL. Eukaryotic regulatory RNAs: an answer to the ‘genome complexity’ conundrum. Genes Dev. 2007;21:11–42.
23. Hangerau MJ, Vaughn IW, McNamur MT. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013;9:e1003569.

24. Jacquier A. The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs. Nat Rev Genet. 2009;10:833–44.

25. Yagan O, Krebs JE. Non-coding but non-expendable: transcriptional regulation by large noncoding RNA in eukaryotes. Biochem Cell Biol. 2007;85:484–96.

26. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol. 2010;220:126–39.

27. Leeper NJ, Maegdefessel L. Non-coding RNAs: key regulators of smooth muscle cell fate in vascular disease. Cardiovasc Res. 2018;114:611–21.

28. Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, Goodfellow P, Lovell-Badge R. Circular transcripts of the tests-determining gene Sry in adult mouse testis. Cell. 1993;73:1019–30.

29. Menczak S, Jens M, Elefsonioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.

30. Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12:381–8.

31. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, et al. In vivo identification of tumor-suppressive PTEN cell RNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011;147:382–95.

32. Cesana M, Cavicchioli D, Legnini I, Santini T, Sthandier O, Chinappi M, Weiss S, Renaldi V, Dabbene F, Conforti M, et al. A class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.

33. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjaers Peter S, Lovell-Badge R. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell. 1993;73:1019–30.

34. Poliseno L, Salmena L, Zhang J, Carver B, Haveman MJ, Pandolfi PP. A coding-independent function of gene and pseudogene miRNAs regulates tumour biology. Nature. 2010;465:1033–8.

35. Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J, Califano A, An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011;147:370–81.

36. Wang X, Zou M, Li J, Wang B, Zhang Q, Liu F, Lu G, Lindgren CM. miR-200c targets miR-22 to modulate H2O2-induced deregulation in human prostate cancer cell lines. PLOS ONE. 2017;12:e0188092.

37. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeillinger R, Plass C. Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and neurodegenerative diseases. Sci Rep. 2015;5:8057.

38. Rong D, Sun H, Li Z, Liu S, Dong Y, Fu K, Yang W, Cao H. An emerging function of circRNA-miRNA-mRNA axis in human diseases. Oncotarget. 2017;8:73271–81.

39. Claesson-Welsh L, Welsh JB. TGF-β and tumour angiogenesis. J Intern Med. 2013;273:114–27.

40. Xiong W, Jiang YX, Ai YQ, Liu S, Wu XR, Cui JG, Qin JY, Liu Y, Xia YX, Ju YH, et al. Microarray analysis of Long non-coding RNA expression profile associated with 5-fluorouracil-based Chemoradiation resistance in colorectal Cancer. Biochem. 2018;119:4990–5002.

41. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeillinger R, Plass C. Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and neurodegenerative diseases. Sci Rep. 2015;5:8057.

42. Amirkhah R, Schmitz U, Linnebacher M, Wolkenhauer O, Farazmand A. MicroRNA regulation by large noncoding RNA in eukaryotes. Biochem Cell Biol. 2007;85:484–96.

43. Wang X, Zhang Y, Huang L, Zhang J, Pan F, Li B, Yan Y, Ja B, Liu H, Li S, Zheng W. Decreased expression of hsa_circ_001988 in colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2016;63:419–24.

44. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006;92:23–68.

45. Xie H, Ren X, Xin S, Lan X, Lu G, Lin Y, Yang Y, Yang S, Zeng Z, Liao W, Ding YQ, Liang L. Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. Oncotarget. 2016;7:26680–91.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.